The Niagen Bioscience, Inc. (NASDAQ: NAGE) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a structured view into how this NAD+ and healthy-aging focused bioscience business reports its operations, strategy, and governance. These documents complement the company’s press releases by providing formal detail on financial results, material agreements, equity plans, and other regulatory matters.
For investors tracking NAGE, periodic reports such as Forms 10-K and 10-Q (when available) are central references for understanding revenue drivers like Tru Niagen® consumer supplements, Niagen® ingredient sales, and pharmaceutical-grade Niagen Plus™ IV and injectable products. They also typically describe research and development priorities, intellectual property portfolios around nicotinamide riboside and other NAD+ precursors, and risk factors relevant to the company’s position in the biotechnology and dietary supplement markets.
Current reports on Form 8-K, several of which are summarized in the recent record, document specific events such as quarterly earnings announcements, share repurchase program authorizations, changes to financial outlook, material supply agreements for nicotinamide-beta-riboside chloride, and patent assignment transactions with Queen’s University Belfast. Other filings detail stockholder approvals of equity incentive plan amendments and employee stock purchase plans, which shape dilution and compensation structures.
On Stock Titan, these filings are paired with AI-powered summaries that help explain complex sections, from revenue and margin discussions to the implications of IP and supply agreements. Users can quickly scan key points in 10-K and 10-Q reports, review 8-K event disclosures, and access information relevant to insider and equity activity through forms such as Form 4 when available. Real-time updates from EDGAR ensure that new Niagen Bioscience filings appear promptly, while AI-generated highlights make it easier to interpret how each document fits into the company’s broader NAD+ science and healthy-aging strategy.
Niagen Bioscience, Inc. reported first-quarter 2026 net sales of $31.5 million, up 3% year-over-year, with Tru Niagen® contributing $22.4 million. Gross margin was 63.5%, reflecting a favorable business mix.
Net income was $6.3 million, helped by a $4.8 million gain on the divestiture of the Analytical Reference Standards and Services operating segment, while adjusted EBITDA was $3.8 million. Basic and diluted earnings per share were $0.08 and $0.07, respectively. Cash and cash equivalents totaled $66.5 million with no outstanding borrowings, after using $1.2 million in operating cash flow and repurchasing $2.4 million of common stock.
The company reaffirmed its 2026 outlook for net sales to increase 10–15% year-over-year, excluding the divested segment, and expects slightly higher gross margin. It plans higher sales and marketing and research and development spending, while general and administrative expense is now projected to rise by $3–$4 million.
Niagen Bioscience, Inc. reported higher profitability for the three months ended March 31, 2026, driven by its core Niagen® businesses and a divestiture gain. Net sales rose to $31.5 million from $30.5 million, led by growth in Tru Niagen® consumer products and food-grade Niagen® ingredient sales.
Net income increased to $6.3 million from $5.1 million, helped by a $4.8 million gain on the sale of the analytical reference standards and services segment. Basic and diluted earnings per share were $0.08 and $0.07, respectively. Gross margin remained stable at about 63% as stronger e‑commerce mix offset shifts in ingredient margins.
Operating cash flow swung to a $1.2 million use of cash, mainly due to higher receivables and inventory to support demand. The company ended the quarter with $66.5 million in cash and cash equivalents and repurchased about 490,000 shares for $2.4 million. Management expects existing cash and operating cash flows to cover obligations for at least the next twelve months.
Niagen Bioscience, Inc. is asking stockholders to vote at its 2026 annual meeting on three key items. Stockholders will elect eight directors, ratify the appointment of Crowe LLP as independent auditor for the year ending December 31, 2026, and approve on an advisory basis the compensation of the company’s named executive officers.
The meeting will be held on June 24, 2026 in Los Angeles, with April 27, 2026 set as the record date. There were 79,644,327 shares of common stock outstanding and entitled to vote as of that date. Non‑employee directors receive cash retainers and annual stock option awards, with the cash retainer increasing to $50,000 beginning in 2026 and annual option awards targeted at $80,000 in grant‑date fair value.
For fiscal 2025, the Compensation Committee tied executive annual bonuses mainly to net sales, net income before bonuses, and qualitative corporate and departmental goals. The committee reports that 2025 net sales reached 110% of target and net income before bonuses reached 169% of target, leading to above‑target bonus payouts for the CEO, CFO, and General Counsel.
Niagen Bioscience Chief Executive Officer Robert N. Fried exercised stock options to acquire 20,000 shares of Common Stock at an exercise price of $2.61 per share. He paid the exercise price in cash and, according to the footnotes, has not sold any of the shares received.
Following the exercise, Fried directly holds 1,058,981 shares of Common Stock. He also reports indirect holdings through family-related accounts and trusts, including 12,746 shares held by his sons and additional shares held in separate irrevocable and revocable trusts, while disclaiming beneficial ownership of those indirect securities.
Niagen Bioscience, Inc. announced that its Board of Directors has doubled the company’s share repurchase authorization to $20 million of outstanding common stock, up from the previously approved $10 million program.
Through March 17, 2026, Niagen Bioscience has repurchased approximately $2.6 million of its common stock under this program. The repurchase authorization runs through October 31, 2027, unless earlier completed, suspended, modified, or terminated by the Board. Repurchases may occur from time to time via open market purchases, privately negotiated transactions, or trading plans, and the company is not obligated to repurchase any specific amount.
Niagen Bioscience, Inc. reported strong growth for 2025, with net sales rising 30% to $129.4 million and gross margin improving 250 basis points to 64.3%. Net income more than doubled to $17.4 million, or $0.22 basic EPS, and Adjusted EBITDA increased to $20.4 million.
The company ended 2025 with $64.8 million in cash and no outstanding borrowings, supported by $13.5 million of operating cash flow. Tru Niagen and Niagen ingredient sales grew 27% and 45%, respectively, and 2026 guidance calls for 10–15% net sales growth and slightly higher margins as it invests in marketing, R&D, and infrastructure.
Niagen Bioscience, Inc. is a Delaware-based bioscience company focused on healthy aging through nicotinamide adenine dinucleotide (NAD+) science. It sells Tru Niagen dietary supplements and Niagen ingredients globally, and is developing pharmaceutical applications that have not yet generated revenue.
Net sales grew to approximately $129.4 million in 2025 from $99.6 million in 2024, a 30% increase and an 18% compound annual growth rate from 2021 to 2025. Growth was led by the consumer products segment at $97.7 million and ingredients at $28.7 million. No customer represented more than 10% of 2025 sales.
The company strengthened its balance sheet, ending 2025 with about $64.8 million in cash and net working capital of $19.4 million, and has an undrawn $10 million credit line. In February 2026 it agreed to sell its analytical reference standards and services segment to concentrate on core NAD+ consumer, ingredient, and pharmaceutical opportunities, supported by an extensive patent portfolio and over 300 research collaborations.
Niagen Bioscience, Inc. is reshaping its business by selling substantially all assets of its analytical reference standards and services unit, operated through ChromaDex, Inc. and ChromaDex Analytics, Inc., to VHG Labs, part of LGC Group, in an all-cash transaction that closed on February 24, 2026. The divestiture is described as part of a broader strategy to exit non-core activities so the company can concentrate on its NAD+ science platform, intellectual property, and commercial growth initiatives in healthy aging and longevity. Niagen will also provide certain operational and administrative transition services to the buyer for up to six months after closing in exchange for service fees recognized as the services are performed.
Lopez Carlos Luis reported acquisition or exercise transactions in this Form 4 filing.
Niagen Bioscience, Inc. reported that its SVP and General Counsel, Carlos Luis Lopez, received a grant of employee stock options covering 41,420 shares on the reported grant date. The options were awarded at no purchase price on grant and will vest in four equal annual installments on each anniversary of the grant date.